Qishenyiqi pills on the secondary prevention of coronary heart disease clinical observation_0.docVIP

  • 6
  • 0
  • 约5.78千字
  • 约 5页
  • 2017-05-05 发布于浙江
  • 举报

Qishenyiqi pills on the secondary prevention of coronary heart disease clinical observation_0.doc

Qishenyiqi pills on the secondary prevention of coronary heart disease clinical observation_0

 PAGE \* MERGEFORMAT 5 Qishenyiqi pills on the secondary prevention of coronary heart disease clinical observation [Keywords:] Coronary heart disease; Qishenyiqi pills, secondary prevention Since November 2003 has been our affiliated hospitals Qishenyiqi pills in the treatment coronary heart disease, and with the comprehensive effect of aspirin, the incidence of endpoint events compared to determine whether it can be used as secondary prevention of coronary heart disease medication. now the results reported below . 1 Materials and Methods 1.1 In 1980 the diagnostic criteria with reference to medical academic conference on “naming and diagnosis of coronary heart disease recommend the standard” [1], the standard diagnostic criteria under 1.2 General information, patients were selected 182 cases were randomly divided into 2 groups. The treatment group 121 cases, 83 males and 38 females, aged 39 to 74 years, mean 58.8 years, the shortest duration of 15 d, up to 18 years, an average of 6.5 years, including 16 cases of hypertension, diabetes mellitus in 5 cases, 12 cases of high cholesterol, and high acid glycerol in 48 cases, the control group 61 cases were 42 males and 19 females, aged 40 to 75 years, mean 57.8 years, the shortest duration of 15 d, up to 16 years, with an average of 5.9 years, of which eight cases of hypertension, diabetes 2 cases, 15 cases of high cholesterol .2 group of patients in age, clinical symptoms and complications and so there was no significant difference in treatment is comparable .1.3 treatment group: Qishenyiqi taking pills (Tasly Pharmaceutical Limited production, Zhunzi: Ingredients: astragalus, red sage root, notoginseng, drop sesame oil, etc.), each 0.5 g, 3 times a day. as the observation period of 1.5 years. Control group: taking enteric-coated aspirin (Tasly Pharmaceutical Co., Ltd. to offer Zhunzi: Each 25 mg), each 0.1 g, day 1. Observation period of 1.5 years as . 1.4 Observation items

文档评论(0)

1亿VIP精品文档

相关文档